Could this I-O combo treat metastatic prostate cancer? by Arlene Weintraub Thursday, November 14, 2019 Combining a checkpoint inhibitor with an anti-TFG-beta drug was effective in mouse models of metastatic prostate cancer, MD Anderson researchers said.
Could stem cell transplants make I-O work in resistant lymphoma? by Angus Liu Friday, August 2, 2019 Transplanting T-cells to immunotherapies could lead to better results in non-Hodgkin lymphoma, Mount Sinai scientists have found.
Idera’s TLR9-Yervoy combo works in PD-1-refractory melanoma by Angus Liu Friday, December 14, 2018 Idera touts higher response rate from the combo than Yervoy alone and a 76.5% disease control rate.
Gritstone Oncology files for $80M IPO by Amirah Al Idrus Thursday, August 23, 2018 After raising more than $194 million in venture capital, Gritstone is looking to raise up to $80 million in its IPO.
Gritstone, BMS to trial immunotherapy combos in solid tumors by Amirah Al Idrus Thursday, July 19, 2018 Gritstone Oncology and Bristol-Myers Squibb will start a phase 1 trial of a combination immunotherapy by year end.
Idera's dermatomyositis drug flops in phase 2 by Amirah Al Idrus Tuesday, June 12, 2018 Idera Pharmaceuticals' TLR antagonist, IMO-8400, failed to improve skin symptoms in adults with dermatomyositis.
Nektar slips on reduced response rates for Opdivo combo by Amirah Al Idrus Thursday, May 17, 2018 The latest update from Nektar and Bristol-Myers' immuno-oncology combo showed a drop in response rate for three cancers.
Bristol-Myers allies with Illumina to create cancer tests by Nick Paul Taylor Monday, April 16, 2018 The partners will use Illumina’s NGS capabilities to create IVDs that assess tumor mutation burden and other potentially predictive biomarkers.
BMS makes history with major multibillion-dollar Nektar drug pact by Nick Paul Taylor Wednesday, February 14, 2018 Bristol-Myers is committing $3.6 billion to a deal that gives Nektar most of the profits and freedom to develop the drug in other combinations.
